Exenatide (GLP-1 receptor agonist) adds significant value to type 2 diabetes management through glucose-dependent insulin secretion, weight loss, and potential beta-cell preservation — clinical evidence review.
Key findingExenatide (GLP-1 receptor agonist) adds significant value to type 2 diabetes management through glucose-dependent insulin secretion, weight loss, and
What the researchers found
Exenatide (GLP-1 receptor agonist) adds significant value to type 2 diabetes management through glucose-dependent insulin secretion, weight loss, and potential beta-cell preservation — clinical evidence review.
Why it matters
Relevant for peptide research.
How the study worked
research study.
What this study cannot tell us
See abstract.
How to read the evidence
emerging evidence.
When this study was published
Published in 2009.
The bigger picture
Advances peptide research.
Questions still open
- Further research needed.
Common questions
What was studied?
What was found?
Read the original research
Does glucagon-like peptide-1 receptor agonist therapy add value in the treatment of type 2 diabetes? Focus on exenatide.
Diabetes research and clinical practice, 86 Suppl 1, S26-34
Citation
van Genugten, Renate E; van Raalte, Daniël H; Diamant, Michaela. (2009). Does glucagon-like peptide-1 receptor agonist therapy add value in the treatment of type 2 diabetes? Focus on exenatide.. Diabetes research and clinical practice, 86 Suppl 1, S26-34. https://doi.org/10.1016/S0168-8227(09)70006-3